Purple Biotech Identifies Potential New Serum Biomarker For Its Lead Oncology Therapeutic Candidate CM24: Associated With 79% Reduction In Risk Of Death
Purple Biotech Identifies Potential New Serum Biomarker For Its Lead Oncology Therapeutic Candidate CM24: Associated With 79% Reduction In Risk Of Death
REHOVOT, Israel, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced it has identified serum CEACAM1 as an additional new potential blood biomarker that may help determine which metastatic pancreatic ductal adenocarcinoma (PDAC) patients are most likely to benefit from treatment with CM24. CM24 is a humanized monoclonal antibody that blocks CEACAM1 binding thereby inhibits its activity. CEACAM1 is overexpressed on certain tumor cells, immune cells, and neutrophils extracellular traps (NETs).Patients with serum CEACAM1 within a defined range prior to treatment demonstrated increased overall survival (OS) and progression free survival (PFS) when treated with CM24
治疗前血清CEACAM1在确定范围内的患者，接受CM24治疗后表现出提高的总生存率（OS）和无进展生存率（PFS）
Definition of serum biomarkers for patient selection offers a substantial advantage in developing treatments for cancer
定义血清生物标志物以供病人选择，在癌症治疗研发中具有重大优势
CM24, a CEACAM1 inhibitor, is currently being evaluated in a Phase 2 randomized pancreatic cancer study, with topline results expected in Q4 of 2024
CM24是CEACAM1抑制剂，目前正在进行第2期随机胰腺癌研究评估，预计于2024年第四季度发布最终结果
REHOVOT, Israel, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced it has identified serum CEACAM1 as an additional new potential blood biomarker that may help determine which metastatic pancreatic ductal adenocarcinoma (PDAC) patients are most likely to benefit from treatment with CM24. CM24 is a humanized monoclonal antibody that blocks CEACAM1 binding thereby inhibits its activity. CEACAM1 is overexpressed on certain tumor cells, immune cells, and neutrophils extracellular traps (NETs).
以色列雷霍沃特，2024年11月4日（环球新闻社）-- 紫生物技术有限公司（"紫生物技术"或"该公司"）（纳斯达克/特拉维夫证券交易所：PPBT），一家开发首创类治疗方法，用以克服肿瘤免疫逃逸和药物抵抗的临床阶段公司，今日宣布已确定血清CEACAM1作为可能有助于判断何种转移性胰腺导管腺癌（PDAC）患者最可能受益于CM24治疗的新潜在血液生物标志物。CM24是一种人源化单克隆抗体，可阻止CEACAM1的结合，从而抑制其活性。CEACAM1在特定肿瘤细胞、免疫细胞和中性粒细胞外围陷阱（NETs）上过表达。
译文内容由第三方软件翻译。
